Profile
| Metric | Value |
|---|---|
| Full Name | Monte Rosa Therapeutics, Inc. |
| Ticker | NASDAQ: GLUE |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | monterosatx.com |
| Employees | 142 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $23.28 | |
| Price, 1D Change | +45.41% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | 76.23 | |
| Beta | 1.02 | |
| Revenue | $76M | |
| Revenue, 1Y Change | +100.00% | |
| EPS | -$0.98 | |
| EPS, 1Y Change | +62.65% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$0.98 | |
| EPS Estimate | -$0.20 | |
| EPS Est. Change | +80.01% | |
| Revenue | $75.62M | |
| Revenue Estimate | $136.47M | |
| Revenue Est. Change | +80.46% | |
| Current Price | $23.28 | |
| Price Target | - | $22.00 |
| Price Tgt. Change | - | -5.50% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.42 | -$2.63 | -8.82% | |
| -$1.21 | -$0.98 | +18.84% | |
| -$0.20 | N/A | +80.01% | |
| -$1.32 | N/A | -34.05% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $15.15M | $0.00 | -100.00% | |
| $59.78M | $75.62M | +26.51% | |
| $136.47M | N/A | +80.46% | |
| $55.70M | N/A | -26.34% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +256.78% | |
| Price, 3Y | +192.46% | |
| Market Cap, 1Y | +277.72% | |
| Market Cap, 3Y | +286.11% | |
| Revenue, 1Y | +100.00% | |
| Revenue, 3Y | +100.00% | |
| EPS, 1Y | +62.65% | |
| EPS, 3Y | +38.11% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $23.28 | |
| SMA 200 | $7.89 | |
| SMA 200 vs Price | -66.09% | |
| SMA 50 | $15.29 | |
| SMA 50 vs Price | -34.32% | |
| Beta | 1.02 | |
| ATR | $1.81 | |
| 14-Day RSI | 72.83 | |
| 10-Day Volatility | 244.01% | |
| 1-Year Volatility | 99.86% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $75.62M | |
| EPS | -$0.98 | |
| Gross Profit | $67.50M | |
| Gross Margin | 89.26% | |
| Operating Profit | -$81.11M | |
| Operating Margin | -107.26% | |
| Net Income | -$72.70M | |
| Net Margin | -96.14% | |
| EBITDA | -$72.99M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.19 | |
| 2.40 | ||
| 2.40 | ||
| - | ||
| 8 | ||
| 2.98 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 76.23 | |
| 8.35 | ||
| 6.17 | ||
| 69.17 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $222.94M | |
| $224.25M | ||
| $438.73M | ||
| $377.44M | ||
| $215.80M | ||
| $156.95M | ||
| Total Debt | $42.72M | |
| $3.71M | ||
| $17.22M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $156.73M | ||
| $156.73M | ||
| $8.12M | ||
| $35.17M | ||
| $8.12M | ||
| $0.00 | ||
| $2.57M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| $42.00M | ||
| -$44.45M | ||
| $98.89M | ||
| Capex | $3.99M | |
| $38.01M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | → | |
| Wells Fargo | → | |
| Wells Fargo | → | |
| Wedbush | → | |
| LifeSci Capital | ||
| Wells Fargo | → | |
| Wedbush | → | |
| Wells Fargo | → | |
| Piper Sandler | → | |
| Wedbush | → |
Analyst sentiment
Institutional ownership
Screeners with GLUE
Data Sources & References
- GLUE Official Website www.monterosatx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1826457/000119312525268045/0001193125-25-268045-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1826457/000095017025042344/0000950170-25-042344-index.htm
- GLUE Profile on Yahoo Finance finance.yahoo.com/quote/GLUE
- GLUE Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/glue
FAQ
What is the ticker symbol for Monte Rosa Therapeutics, Inc.?
The ticker symbol for Monte Rosa Therapeutics, Inc. is NASDAQ:GLUE
Does Monte Rosa Therapeutics, Inc. pay dividends?
No, Monte Rosa Therapeutics, Inc. does not pay dividends
What sector is Monte Rosa Therapeutics, Inc. in?
Monte Rosa Therapeutics, Inc. is in the Healthcare sector
What industry is Monte Rosa Therapeutics, Inc. in?
Monte Rosa Therapeutics, Inc. is in the Biotechnology industry
What country is Monte Rosa Therapeutics, Inc. based in?
Monte Rosa Therapeutics, Inc. is headquartered in United States
When did Monte Rosa Therapeutics, Inc. go public?
Monte Rosa Therapeutics, Inc. initial public offering (IPO) was on June 24, 2021
Is Monte Rosa Therapeutics, Inc. in the S&P 500?
No, Monte Rosa Therapeutics, Inc. is not included in the S&P 500 index
Is Monte Rosa Therapeutics, Inc. in the NASDAQ 100?
No, Monte Rosa Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Monte Rosa Therapeutics, Inc. in the Dow Jones?
No, Monte Rosa Therapeutics, Inc. is not included in the Dow Jones index
When was Monte Rosa Therapeutics, Inc. last earnings report?
Monte Rosa Therapeutics, Inc.'s most recent earnings report was on November 6, 2025
When does Monte Rosa Therapeutics, Inc. report earnings?
The next expected earnings date for Monte Rosa Therapeutics, Inc. is March 19, 2026